Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, Inc. (NASDAQ:TVTX), recently executed a stock transaction involving the sale of company shares. According to a recent SEC filing, Cline sold 5,192 shares of Travere Therapeutics at a price of $20.12 per share, totaling $104,463. This sale was conducted on February 3, 2025, as part of a mandated "sell to cover" transaction to fulfill tax obligations related to vested restricted stock units. The transaction comes as Travere’s stock trades near its 52-week high of $21.56, having delivered an impressive 155% return over the past year.
Additionally, on January 31, 2025, Cline acquired 21,500 shares of common stock and 58,000 employee stock options. These acquisitions were recorded at no cost in the filing. Following these transactions, Cline holds 90,038 shares of Travere Therapeutics common stock directly. According to InvestingPro data, analysts maintain a bullish outlook on the stock, with price targets ranging from $18 to $45. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report for deeper analysis of Travere’s market position and growth potential.
In other recent news, Travere Therapeutics, Inc., a biopharmaceutical company, announced plans to conduct a public offering of its common stock. The finalization and details of the offering are dependent on market and other conditions. Jefferies and Leerink Partners are managing the offering, which is subject to an automatic shelf registration statement previously filed with the Securities and Exchange Commission. The company has not yet disclosed specific details regarding the use of proceeds from the offering. These developments are part of the company’s ongoing mission to provide therapies for patients with rare diseases. However, it should be noted that the proposed offering is subject to market conditions and the satisfaction of customary closing conditions. The information provided is based on a press release statement from Travere Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.